AMG 827 in Subjects With Moderate to Severe Crohn's Disease

Inclusion Criteria:

- Diagnosed with ileal, ileo-colonic, or colonic Crohn's disease for a minimum of 6
months prior to initiating Study Product

- Moderately to severely active Crohn's disease, as defined by a CDAI score >250 and
<450 at baseline

- Evidence of active inflammation

Exclusion Criteria:

- Short bowel syndrome

- Stricture with obstructive symptoms within 3 months

- Bowel surgery within 3 months

- Ileostomy and/or colostomy

- Any gastric or intestinal pouch

- Ulcerative colitis

- Evidence of an infected abscess

- Bowel perforation or evidence of noninflammatory obstruction during the 6 months
Stool positive for C. Difficile toxin at screening

- Presence of active infection requiring treatment

- Serious infection within 8 weeks

- Significant concurrent medical conditions

- Pregnant or breast feeding

- Significant Laboratory abnormalities

- Any anti-TNF agent within 2 months

- Steroid enemas within 2 weeks

- Tysabri (natalizumab) within 1 year

- Biologic agents (eg, ustekinumab), experimental procedures, or live vaccines within 3
months

- Cyclosporine, mycophenolate mofetil, sirolimus (rapamycin),thalidomide or tacrolimus
within 2 months